首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1623513

敗血症診斷市場（按技術、產品、病原體、檢測類型和地區劃分）2024 年至 2031 年

Sepsis Diagnostics Market By Technology, By Product, By Pathogen, By Testing Type & Region for 2024-2031

出版日期: 2024年06月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

敗血症診斷市場評估，2024 年至 2031 年

敗血症診斷市場預計到 2023 年將成長 6.872 億美元，到 2031 年將成長 14.043 億美元，預測期內複合年增長率為 8.3%。全球範圍內敗血症患者數量的不斷增加以及人們對該疾病嚴重性的認識不斷提高，推動了對敗血症診斷的需求。分子診斷和生物標記等診斷技術的快速發展有助於早期發現和治療，改善患者的治療效果。此外，尤其是已開發國家的政府計劃和醫療保健系統資金鼓勵使用現代診斷設備。醫療相關性感染的增加增加了對準確、快速敗血症診斷的需求。

敗血症診斷市場定義/概述

敗血症診斷是指用於識別敗血症的程序和技術，敗血症是一種因身體對感染的過度反應而導致的危及生命的疾病。早期診斷對於提高存活率至關重要。血液檢測、分子診斷和生物標記識別都是用於檢測體內病原體和發炎反應的診斷技術。這些測試使醫療保健專業人員能夠更快地發現敗血症，從而可以更快地進行治療並減少因延遲幹預而導致的器官衰竭和死亡等併發症。

這些診斷方法分析生物標記、感染和免疫反應，以確定是否有敗血症。快速且準確的診斷可以及時幹預，減少器官衰竭的機會並提高患者的存活率。敗血症診斷可在醫院、實驗室和護理點使用，幫助指導臨床決策、監測患者狀況並優化治療方法，從而獲得更好的醫療保健結果。

敗血症診斷的未來在於開發更快、更準確和個人化的診斷工具。人工智慧、機器學習和生物標記研究的進步將使更早發現敗血症成為可能並改善患者的治療效果。由於即時診斷和即時監測系統能夠在重症監護環境中提供即時結果，因此有望得到更廣泛的應用。

慢性疾病和醫院內感染將如何影響敗血症診斷市場對先進診斷工具的需求？

慢性疾病和醫院內感染將對敗血症診斷市場對先進診斷設備的需求產生重大影響。患有糖尿病、癌症和呼吸系統疾病等慢性疾病的患者更容易受到感染，並可能發展為敗血症。隨著這些慢性疾病在世界範圍內的發病率不斷增加，醫療保健提供者正在尋求更快、更準確的診斷技術，以便更早發現敗血症。對快速診斷的迫切需求正在推動對新技術的投資，以改善病原體的檢測和監測。

此外，醫院內感染 (HAI) 已成為醫療保健環境中的主要問題，導致住院患者敗血症發生率不斷增加。醫院感染管理的複雜性涉及實施先進的診斷技術，以便快速識別病原體及其抗生素敏感性。隨著醫療保健系統努力改善患者治療效果並降低敗血症相關死亡率，對改進診斷解決方案的需求也在不斷增長，從而推動了敗血症診斷市場對快速幹預和有針對性的治療的需求。受到重視。

先進診斷技術的高成本是否限制了其在敗血症診斷市場的採用？

目前診斷技術成本高是敗血症診斷產業發展的一大阻礙因素，尤其是在資源匱乏的醫療保健環境中。許多醫院和診所，特別是發展中國家的醫院和診所都面臨資金限制，無法獲得尖端診斷技術。這些醫院通常依靠較舊的方法來識別敗血症，但這些方法效率較低且更耗時，可能會影響患者的治療結果。因此，改進的診斷方法的潛在益處仍未充分利用，導致敗血症死亡率增加。

此外，實施和維護這項先進技術相關的成本可能會阻止醫療保健提供者進行大量支出。持續的培訓和支援的需求進一步加劇了這些限制，從而增加了整體成本。缺乏對高成本診斷的投資可能導致診斷不足和延遲治療的循環，從而阻礙敗血症診斷行業的發展。

The sepsis diagnostics market size was valued at USD 687.2 Million in 2023 and is projected to grow 1404.3 Million by 2031, exhibiting a CAGR of 8.3% during the forecast period. Rising sepsis cases around the world combined with increased awareness of the condition's severity are driving demand for sepsis diagnostics. Rapid advances in diagnostic technology such as molecular diagnostics and biomarkers are accelerating early identification and treatment, resulting in better patient outcomes. Furthermore, government programs and funding in healthcare systems, particularly in developed countries, promote the use of modern diagnostic equipment. The increasing prevalence of healthcare-associated infections is exacerbating the need for accurate and rapid sepsis diagnosis.

Sepsis Diagnostics Market: Definition/ Overview

Sepsis diagnostics refers to the procedures and technologies used to identify sepsis, which is a life-threatening condition caused by the body's overreaction to infection. Early diagnosis is crucial for increasing survival rates. Blood testing, molecular diagnostics, and biomarker identification are all diagnostic techniques used to detect pathogens and inflammatory responses in the body. These tests enable healthcare practitioners to detect sepsis rapidly allowing for immediate treatment and decreasing complications such as organ failure or death caused by delayed intervention.

These diagnostics analyze biomarkers, infections, and immune responses to determine the existence of sepsis. Rapid and precise diagnosis allows for timely intervention which reduces the chance of organ failure and increases patient survival rates. Sepsis diagnostics are utilized in hospitals, laboratories, and point-of-care settings to help guide clinical decisions, monitor patient states, and optimize treatment approaches resulting in better healthcare outcomes.

The future of sepsis diagnostics lies in the development of faster, more accurate, and personalized diagnostic tools. Advancements in artificial intelligence, machine learning, and biomarker research will enable earlier detection of sepsis, improving patient outcomes. Point-of-care testing and real-time monitoring systems are expected to become more widespread offering immediate results in critical care settings.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How do Chronic Diseases and Hospital-Acquired Infections Influence the Demand for Advanced Diagnostic Tools in the Sepsis Diagnostics Market?

Chronic diseases and hospital-acquired infections have a substantial impact on the demand for enhanced diagnostic instruments in the sepsis diagnostics market. Patients with chronic disorders such as diabetes, cancer, and respiratory problems are more vulnerable to infections which can progress to sepsis. As the global frequency of these chronic diseases rises, healthcare providers are looking for faster and more accurate diagnostic techniques to detect sepsis in its early stages. This important need for fast diagnosis drives investments in new technologies that improve pathogen detection and monitoring.

Furthermore, hospital-acquired infections (HAIs) are becoming a major concern in healthcare settings, resulting in the increasing incidence of sepsis among hospitalized patients. The complexity of HAI management involves the deployment of sophisticated diagnostic technologies capable of swiftly identifying the causative agents and their antibiotic susceptibility. As healthcare systems work to improve patient outcomes and reduce sepsis-related mortality, the demand for improved diagnostic solutions will increase, emphasizing the necessity of prompt intervention and focused therapeutics in the sepsis diagnostics market.

How Does the High Cost of Advanced Diagnostic Technologies Serve as a Restraint to Widespread Adoption in the Sepsis Diagnostics Market?

The high cost of modern diagnostic technologies severely limits widespread use in the sepsis diagnostics industry, especially in resource-constrained healthcare settings. Many hospitals and clinics, particularly in developing countries, confront financial constraints that restrict them from adopting cutting-edge diagnostic technologies. These hospitals frequently rely on older methods for identifying sepsis which can be less effective and slower, affecting patient outcomes. As a result, the potential benefits of improved diagnostics remain underutilized contributing to greater sepsis death rates.

Furthermore, the cost burden associated with deploying and maintaining this advanced technology may discourage healthcare providers from making critical expenditures. This constraint is exacerbated by the requirement for continual training and assistance which increases the overall cost. Reluctance to invest in high-cost diagnostics might lead to a loop of underdiagnosis and delayed treatment impeding growth in the sepsis diagnostics sector.

Category-Wise Acumens

How do Advancements in Blood Culture Technology Improve the Detection of Pathogens in Sepsis Cases?

Blood culture media are dominant in the sepsis diagnostics market primarily due to their crucial role in identifying the pathogens responsible for sepsis. These media facilitate the growth of bacteria and fungi from blood samples enabling accurate and timely diagnosis. The ability to detect a wide range of microorganisms including those that are fastidious or present in low concentrations, makes blood culture a gold standard in sepsis diagnostics. As early detection is vital for effective treatment, the reliability and sensitivity of blood culture media significantly contribute to their prevalence in clinical settings.

Furthermore, advancements in blood culture technology such as automated systems that monitor growth and provide rapid results enhance their effectiveness. Innovations like continuous monitoring and improved sensitivity have expanded their utility in diagnosing sepsis even in challenging cases. As healthcare systems increasingly prioritize early intervention and precise diagnostics to improve patient outcomes, the demand for blood culture media continues to grow solidifying their dominant position in the market.

How Does the Diversity and Evolution of Sepsis-Causing Pathogens Challenge Traditional Diagnostic Methods?

Molecular diagnostics is more dominant in the sepsis diagnostics market due to its ability to provide rapid and accurate identification of pathogens causing sepsis. Unlike traditional culture methods which can take days to yield results, molecular techniques such as polymerase chain reaction (PCR) and next-generation sequencing deliver results in a matter of hours. This speed is crucial for timely treatment decisions, significantly improving patient outcomes and reducing mortality rates associated with sepsis.

Furthermore, molecular diagnostics can detect a wide variety of pathogens including bacteria, viruses, and fungi, in a single test. This extensive detection capability is critical given the diversity and evolution of sepsis-causing pathogens. As healthcare practitioners recognize the value of early intervention, the demand for better diagnostic technologies grows. The growing use of point-of-care testing increases the accessibility and utility of molecular diagnostics in critical care settings cementing its dominance in the sepsis diagnostics market.

Sepsis Diagnostics Market

Report Methodology

Country/Region-wise Acumens

How do Increased Awareness and Education among Healthcare Professionals and Patients Affect the Sepsis Diagnostics Market in the North American Region?

North America dominates the sepsis diagnostics market because of its advanced healthcare infrastructure and large spending on medical research & development. The region is home to many top diagnostic firms and research organizations that promote innovation in sepsis detection methods. This has resulted in the development of cutting-edge treatments like molecular diagnostics and quick testing systems which allow healthcare providers to identify sepsis more effectively and efficiently.

Furthermore, the rising occurrence of sepsis, together with increased awareness among healthcare professionals and patients drives market expansion. The presence of well-established healthcare systems promotes the use of advanced diagnostic technologies which improves patient outcomes. Furthermore, legislative and financing initiatives in North America promote the development and commercialization of novel diagnostic technology. As a result, North America continues to dominate the sepsis diagnostics industry using its strengths in technology, research, and healthcare delivery.

How Does the Developing Healthcare Infrastructure Influence the Adoption of Modern Diagnostic Tools for Sepsis in the Asia-Pacific Region?

Asia Pacific is the fastest-growing area in the sepsis diagnostics market owing to a rapidly growing patient population fuelled by rising infection rates, chronic diseases, and an aging demographic. The region's developing healthcare infrastructure combined with significant government investment in healthcare innovations encourages the use of modern diagnostic tools. As knowledge of sepsis and its serious effects develops, healthcare providers are focussing more on strengthening diagnostic capabilities to ensure timely and successful treatment.

Furthermore, the growth of biotechnology and pharmaceutical companies in countries such as China and India creates a competitive climate for producing sophisticated diagnostics. The increasing demand for point-of-care testing and molecular diagnostics is also propelling expansion in this sector. Furthermore, the rising prevalence of hospital-acquired infections and the necessity for rapid diagnostic solutions in healthcare facilities highlight the importance of effective sepsis diagnostics. These factors combine to position Asia Pacific as a major participant in the global sepsis diagnostics market.

Competitive Landscape

The Sepsis Diagnostics Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the sepsis diagnostics market include:

Abbott Laboratories, Becton Dickinson and Company, BioMerieux, Luminex, Danaher, T2 Biosystems, Thermo Fisher Scientific, Roche Diagnostics, Bruker, Immunexpress.

Latest Developments

In April 2024, The US Food and Drug Administration (FDA) approved Prenosis' AI tool Sepsis ImmunoScore to diagnose sepsis. This authorization, obtained through the De Novo procedure, is the first FDA approval of an AI/machine learning (ML) software as a medical device (SaMD) for sepsis detection and prediction.

In May 2024, Cytovale, a medical diagnostics company, announced the publication of data demonstrating that its sepsis diagnosis tool IntelliSep has a negative predictive value of 97.5 percent. The FDA-approved IntelliSep technology allows for the rapid detection of sepsis in adults who exhibit signs and symptoms of infection by squeezing white blood cells to characterize their reactions to infection.

1 INTRODUCTION OF GLOBAL SEPSIS DIAGNOSTICS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL SEPSIS DIAGNOSTICS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

5.1 Overview
5.2 Microbiology
5.3 Molecular Diagnostics
5.4 Immunoassays

6 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

6.1 Overview
6.2 Assay and reagents
6.3 Blood culture media
6.4 Instruments

7 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN

7.1 Overview
7.2 Fungal sepsis
7.3 Bacterial sepsis

8 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TESTING TYPE

8.1 Overview
8.2 Laboratory Tests
8.3 Point-of-care Tests

9 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East & Africa

10 GLOBAL SEPSIS DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Becton, Dickinson and Company
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 BioMerieux
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Luminex
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Danaher
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 T2 Biosystems
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Thermo Fisher Scientific
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Roche Diagnostics
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Bruker
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Immunexpress
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments